Musosal tumour necrosis factor α in diverticular disease of the colon is overexpressed with disease severity

Colorectal Disease

Volumn 14, Issue 5, 2012, Pages

  Tursi, A ^a   Elisei, W ^b   Brandimarte, G ^c   Giorgetti, G M ^d   Inchingolo, C D ^e   Nenna, R ^e   Picchio, M ^f   Giorgio, F ^g   Ierardi, E ^g  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c Ospedale 'Cristo Re'   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

^e ASL BAT   (Italy)

^f UOC di Chirurgia Generale   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Diverticular disease; Diverticulitis; Segmental colitis associated with diverticulosis; Tumour necrosis factor

Indexed keywords

MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CLINICAL ARTICLE; COLITIS; COLON DIVERTICULOSIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; ULCERATIVE COLITIS;

AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; DIVERTICULITIS, COLONIC; DIVERTICULOSIS, COLONIC; FEMALE; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859223555     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2012.02926.x     Document Type: Article

References (43)

1. Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009; 30: 532-46.
2. Tursi A. New physiopathological and therapeutic approaches to diverticular disease disease of the colon. Expert Opin Pharmacother 2007; 8: 299-307.
3. Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
4. Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
5. Reinecker H-C, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1b by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
6. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-82.
7. Berner B, Akca D, Jung T et al. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27: 1128-35.
8. Murch SH, Braegger CP, Walker-Smith JA et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-9.
9. Hassan C, Ierardi E, Burattini O et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 39: 811-7.
10. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 1993; 30: 1443-53.
11. Fiorino G, Szabò H, Walter F, Malesci A, Peyrin-Biroulet L, Danese S. Adalimumab in Crohn's disease: tips and tricks after 5years of clinical experience. Curr Med Chem 2011; 18: 1230-8.
12. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
13. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
14. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med 2004; 350: 876-85.
15. Baert FJ, D'Haens GR, Peeters M et al. Tumour necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-8.
16. Harpaz N, Sachar DB. Segmental colitis associated with diverticular disease and other IBD look-alikes. J Clin Gastroenterol 2006; 40: S132-5.
17. Lamps LW, Knapple WL. Diverticular disease-associated segmental colitis. Clin Gastroenterol Hepatol 2007; 5: 27-31.
18. Tursi A. Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity? Dig Dis Sci 2011; 56: 27-34.
19. Ierardi E, Meucci G, Hassan C et al. Tumour necrosis factor alpha in segmental colitis associated with diverticula. Dig Dis Sci 2008; 53: 1865-8.
20. Tursi A, Inchingolo CD, Nenna R et al. Pattern of mucosal tumor necrosis factor-alpha expression in segmental colitis associated with diverticula suggests a truly autonomous clinical entity. Inflamm Bowel Dis 2008; 14: 1315-7.
21. Hassan C, Zullo A, Ierardi E et al. Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut 2006; 55: 589-90.
22. Tursi A, Elisei W, Brandimarte G et al. Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis is related to the severity of the endoscopic damage. Dig Liver Dis 2011; 43: 374-9.
23. Elli L, Roncoroni L, Bardella MT et al. Absence of mucosal inflammation in uncomplicated diverticular disease. Dig Dis Sci 2011; 66: 2098-103.
24. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008; 103: 1550-6.
25. Köhler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease. Results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery (EAES). Surg Endosc 1999; 13: 430-6.
26. Pereira JM, Sirlin CB, Pinto PS, Jeffrey RB, Stella DL, Casola G. Disproportionate fat stranding: a helpful CT sign in patients with acute abdominal pain. Radiographics 2004; 24: 703-15.
27. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Maiorano M, Aiello F. The clinical picture of uncomplicated versus complicated diverticulitis of the colon. Dig Dis Sci 2008; 53: 2474-9.
28. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49-55.
29. Tursi A, Elisei W, Brandimarte G et al. The endoscopic spectrum of segmental colitis associated with diverticulosis. Colorectal Dis 2010; 12: 464-70.
30. Rizzello F, Gionchetti P, D'Arienzo A et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 1109-16.
31. Ierardi E, Monno RA, Gentile A et al. Helicobacter heilmannii gastritis: a histological and immunohistochemical trait. J Clin Pathol 2003; 54: 774-7.
32. Ierardi E, Giorgio F, Rosania R et al. Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples: a comparison between immunohistochemistry and real time polymerase chain reaction. Scand J Gastroenterol 2010; 45: 1007-8.
33. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-93.
34. Narayan R, Floch MH. Microscopic colitis as part of the natural history of diverticular disease (Abstract). Am J Gastroenterol 2002; 97(Suppl.): 112.
35. Morini S, Hassan C, Zullo A et al. Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. Aliment Pharmacol Ther 2005; 21: 1385-90.
36. Tursi A, Brandimarte G, Elisei W et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008; 42: 699-703.
37. Cianci R, Iacopini F, Petruzziello L, Cammarota G, Pandolfi F, Costamagna G. Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol 2009; 44: 108-15.
38. Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol 2010; 105: 652-61.
39. Tursi A. Irritable bowel syndrome and diverticular disease: association or misdiagnosis? Am J Gastroenterol 2010; 105: 2293.
40. Macsharry J, O'Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-76.
41. Trespi E, Colla C, Panizza P et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4year follow-up results. Minerva Gastroenterol Dietol 1999; 45: 245-52.
42. Tursi A, Brandimarte G, Daffinà R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 2002; 34: 510-5.
43. Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci 2011; 56: 3112-21.